FIRST MANHATTAN CO. LLC. - BRIDGEBIO PHARMA INC ownership

BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 215 filers reported holding BRIDGEBIO PHARMA INC in Q3 2021. The put-call ratio across all filers is 1.81 and the average weighting 0.5%.

Quarter-by-quarter ownership
FIRST MANHATTAN CO. LLC. ownership history of BRIDGEBIO PHARMA INC
ValueSharesWeighting
Q2 2023$472,828
+3.7%
27,4900.0%0.00%0.0%
Q1 2023$455,784
+117.6%
27,4900.0%0.00%
+100.0%
Q4 2022$209,473
-23.3%
27,4900.0%0.00%0.0%
Q3 2022$273,000
-65.6%
27,490
-68.6%
0.00%
-66.7%
Q2 2022$794,000
+4311.1%
87,490
+21772.5%
0.00%
Q3 2021$18,000
-25.0%
4000.0%0.00%
Q2 2021$24,0000.0%4000.0%0.00%
Q1 2021$24,0004000.00%
Other shareholders
BRIDGEBIO PHARMA INC shareholders Q3 2021
NameSharesValueWeighting ↓
Aisling Capital Management LP 6,068,125$55,099,00039.31%
M28 Capital Management LP 466,200$4,233,0004.74%
Kohlberg Kravis Roberts & Co. L.P. 31,060,971$282,034,0003.75%
Octagon Capital Advisors LP 933,743$8,478,0002.26%
VIKING GLOBAL INVESTORS LP 26,620,991$241,719,0001.11%
HHLR ADVISORS, LTD. 5,362,014$48,687,0001.04%
Cormorant Asset Management, LP 1,469,179$13,340,0001.01%
Knott David M Jr 213,206$1,936,0000.81%
Fernwood Investment Management, LLC 183,900$1,670,0000.72%
HighVista Strategies LLC 105,942$962,0000.58%
View complete list of BRIDGEBIO PHARMA INC shareholders